MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Novartis AG

Open

132.51 1.58

Overview

Share price change

24h

Current

Min

130.35

Max

133.34

Key metrics

By Trading Economics

Income

418M

4B

Sales

660M

14B

P/E

Sector Avg

18.012

35.739

EPS

2.42

Dividend yield

3.23

Profit margin

28.18

Employees

75,883

EBITDA

-5.8B

4.9M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-13.64% downside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.23%

3.08%

Market Stats

By TradingEconomics

Market Cap

1.2B

240B

Previous open

130.93

Previous close

132.51

Technical Score

By Trading Central

Confidence

Bearish Evidence

Novartis AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 paź 2025, 08:54 UTC

Major Market Movers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

15 wrz 2025, 12:07 UTC

Major Market Movers

Monte Rosa Therapeutics Shares Soar on Drug Partnership with Novartis

9 wrz 2025, 10:11 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Tourmaline Bio Shares Surge Premarket on Takeover by Novartis

9 wrz 2025, 05:52 UTC

Acquisitions, Mergers, Takeovers

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

7 sie 2025, 05:47 UTC

Acquisitions, Mergers, Takeovers

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 lip 2025, 14:26 UTC

Earnings

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 lip 2025, 06:49 UTC

Earnings

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 lip 2025, 05:41 UTC

Earnings

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

1 paź 2025, 06:47 UTC

Market Talk

Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

29 wrz 2025, 11:46 UTC

Acquisitions, Mergers, Takeovers

Novartis: Offer to Expire Oct. 27

29 wrz 2025, 11:45 UTC

Acquisitions, Mergers, Takeovers

Novartis Has Started Tender Offer to Buy Tourmaline Bio

12 wrz 2025, 16:11 UTC

Earnings

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

9 wrz 2025, 08:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Novartis Makes Strategically Meaningful Move With Tourmaline Deal -- Market Talk

9 wrz 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Novartis Offering $48 a Share for Tourmaline

9 wrz 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Novartis: Offer Price Values Tourmaline at $1.4B on Fully Diluted Basis

9 wrz 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Tourmaline Bio in Bid to Complement Cardiovascular Pipeline

9 wrz 2025, 05:00 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Tourmaline Bio

11 sie 2025, 11:16 UTC

Earnings

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus -- WSJ

8 sie 2025, 11:26 UTC

Market Talk

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 sie 2025, 11:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 sie 2025, 10:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 sie 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 lip 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 lip 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 lip 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 lip 2025, 07:02 UTC

Market Talk
Earnings

Novartis's Results Look Impressive -- Market Talk

17 lip 2025, 05:09 UTC

Earnings

Novartis 2Q Sales Grew 11% at Constant Currency

17 lip 2025, 05:08 UTC

Earnings

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 lip 2025, 05:06 UTC

Earnings

Novartis: Mehta's Appointment Is Effective March 2026

17 lip 2025, 05:05 UTC

Earnings

Novartis: Harry Kirsch Retires After 22 Years With Company

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

-13.64% downside

12 Months Forecast

Average 113.75 USD  -13.64%

High 129 USD

Low 100 USD

Based on 5 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

3

Hold

1

Sell

Technical Score

By Trading Central

N/A / 112.63Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
help-icon Live chat